164 related articles for article (PubMed ID: 17919235)
1. Urotensin II: a novel vasoactive mediator linked to chronic liver disease and portal hypertension.
Kemp W; Krum H; Colman J; Bailey M; Yandle T; Richards M; Roberts S
Liver Int; 2007 Nov; 27(9):1232-9. PubMed ID: 17919235
[TBL] [Abstract][Full Text] [Related]
2. Urotensin II levels are an important marker for the severity of portal hypertension in children.
Pawar R; Kemp W; Roberts S; Krum H; Yandle T; Hardikar W
J Pediatr Gastroenterol Nutr; 2011 Jul; 53(1):88-92. PubMed ID: 21694541
[TBL] [Abstract][Full Text] [Related]
3. Urotensin II modulates hepatic fibrosis and portal hemodynamic alterations in rats.
Kemp W; Kompa A; Phrommintikul A; Herath C; Zhiyuan J; Angus P; McLean C; Roberts S; Krum H
Am J Physiol Gastrointest Liver Physiol; 2009 Oct; 297(4):G762-7. PubMed ID: 19797237
[TBL] [Abstract][Full Text] [Related]
4. [Measurement of hepatic venous pressure gradient in liver cirrhosis: relationship with the status of cirrhosis, varices, and ascites in Korea].
Kim MY; Baik SK; Suk KT; Yea CJ; Lee IY; Kim JW; Cha SH; Kim YJ; Um SH; Han KH
Korean J Hepatol; 2008 Jun; 14(2):150-8. PubMed ID: 18617762
[TBL] [Abstract][Full Text] [Related]
5. A 3-month course of long-acting repeatable octreotide (sandostatin LAR) improves portal hypertension in patients with cirrhosis: a randomized controlled study.
Spahr L; Giostra E; Frossard JL; Morard I; Mentha G; Hadengue A
Am J Gastroenterol; 2007 Jul; 102(7):1397-405. PubMed ID: 17488248
[TBL] [Abstract][Full Text] [Related]
6. Increased circulating urotensin II in cirrhosis: potential implications in liver disease.
Kemp W; Roberts S; Krum H
Peptides; 2008 May; 29(5):868-72. PubMed ID: 17913301
[TBL] [Abstract][Full Text] [Related]
7. Hepatic venous pressure gradient as a predictor of fibrosis in chronic liver disease because of hepatitis B virus.
Kumar M; Kumar A; Hissar S; Jain P; Rastogi A; Kumar D; Sakhuja P; Sarin SK
Liver Int; 2008 May; 28(5):690-8. PubMed ID: 18433395
[TBL] [Abstract][Full Text] [Related]
8. [Study on the effect of adrenomedulin and urotensin-II on pulmonary hypertension of patients with congenital heart disease].
Wang T; Li SX; Zhang XQ; Gu XH; Song Y; Zhang G; Wu SM
Zhonghua Yi Xue Za Zhi; 2005 Oct; 85(38):2691-5. PubMed ID: 16324296
[TBL] [Abstract][Full Text] [Related]
9. Increased urotensin II plasma levels in patients with cirrhosis and portal hypertension.
Heller J; Schepke M; Neef M; Woitas R; Rabe C; Sauerbruch T
J Hepatol; 2002 Dec; 37(6):767-72. PubMed ID: 12445417
[TBL] [Abstract][Full Text] [Related]
10. Effect of urotensin II on skin microvessel tone in diabetic patients without heart failure or essential hypertension.
Zomer E; de Ridder I; Kompa A; Komesaroff P; Gilbert R; Krum H
Clin Exp Pharmacol Physiol; 2008 Oct; 35(10):1147-50. PubMed ID: 18505448
[TBL] [Abstract][Full Text] [Related]
11. [Plasma prostacyclin (PGI2) levels in peripheral venous, arterial and portal venous blood in cirrhotic patients with portal hypertension and their clinical implication].
Yin J; Leng X; Zhu J
Zhonghua Wai Ke Za Zhi; 1995 Sep; 33(9):563-5. PubMed ID: 8731881
[TBL] [Abstract][Full Text] [Related]
12. Norfloxacin treatment for clinically significant portal hypertension: results of a randomised double-blind placebo-controlled crossover trial.
Kemp W; Colman J; Thompson K; Madan A; Vincent M; Chin-Dusting J; Kompa A; Krum H; Roberts S
Liver Int; 2009 Mar; 29(3):427-33. PubMed ID: 18673434
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of hepatic venous pressure gradient for in-hospital mortality of patients with severe acute alcoholic hepatitis.
Rincon D; Lo Iacono O; Ripoll C; Gomez-Camarero J; Salcedo M; Catalina MV; Hernando A; Clemente G; Matilla A; Nuñez O; Bañares R
Aliment Pharmacol Ther; 2007 Apr; 25(7):841-8. PubMed ID: 17373923
[TBL] [Abstract][Full Text] [Related]
14. Serum laminin P1 levels do not reflect critically elevated portal pressure in patients with liver cirrhosis.
Bahr MJ; Böker KH; Horn W; Günzler V; Manns MP
Hepatogastroenterology; 1997; 44(16):1200-5. PubMed ID: 9261625
[TBL] [Abstract][Full Text] [Related]
15. Increased expression of urotensin II and GPR14 in patients with cirrhosis and portal hypertension.
Liu D; Chen J; Wang J; Zhang Z; Ma X; Jia J; Wang Y
Int J Mol Med; 2010 Jun; 25(6):845-51. PubMed ID: 20428787
[TBL] [Abstract][Full Text] [Related]
16. Relationship between the Fibrotest and portal hypertension in patients with liver disease.
Thabut D; Imbert-Bismut F; Cazals-Hatem D; Messous D; Muntenau M; Valla DC; Moreau R; Poynard T; Lebrec D
Aliment Pharmacol Ther; 2007 Aug; 26(3):359-68. PubMed ID: 17635370
[TBL] [Abstract][Full Text] [Related]
17. Histological-hemodynamic correlation in cirrhosis-a histological classification of the severity of cirrhosis.
Nagula S; Jain D; Groszmann RJ; Garcia-Tsao G
J Hepatol; 2006 Jan; 44(1):111-7. PubMed ID: 16274836
[TBL] [Abstract][Full Text] [Related]
18. Soluble P selectin levels in chronic liver disease: relationship to disease severity.
Vardareli E; Saricam T; Demirustu C; Gulbas Z
Hepatogastroenterology; 2007 Mar; 54(74):466-9. PubMed ID: 17523300
[TBL] [Abstract][Full Text] [Related]
19. The value of serum-ascites albumin gradient for the determination of portal hypertension in the diagnosis of ascites.
Dittrich S; Yordi LM; de Mattos AA
Hepatogastroenterology; 2001; 48(37):166-8. PubMed ID: 11268957
[TBL] [Abstract][Full Text] [Related]
20. Hepatic venous pressure gradient does not correlate with the presence and the severity of portal hypertensive gastropathy in patients with liver cirrhosis.
Bellis L; Nicodemo S; Galossi A; Guarisco R; Spilabotti L; Durola L; Dell'Unto O; Puoti C
J Gastrointestin Liver Dis; 2007 Sep; 16(3):273-7. PubMed ID: 17925921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
